Every 8-K that BioCardia, Inc. Warrant (BCDAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BCDAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCDAW filings page.
BioCardia, Inc. announced an exclusive development and commercialization agreement with CART‑Tech, B.V. for Heart3D™ Fusion Imaging. The Heart3D system is described as a tool to enhance two‑dimensional x‑ray images used for cardiac biotherapeutic delivery and biopsy procedures by fusing those images with annotated pre‑procedure three‑dimensional heart models created from MRI and CT scans.
The companies issued a joint press release about the agreement, and that press release is attached as Exhibit 99.1 to this report.
BioCardia, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is being furnished rather than "filed" with the SEC, so it is not subject to the liabilities of a filed report and is not incorporated by reference into other filings unless explicitly stated.
The 8-K confirms the company’s securities trade on the Nasdaq Capital Market under the tickers BCDA (common stock) and BCDAW (warrants). No financial figures or operational details are included in the 8-K text itself; those details are contained in the furnished press release (Exhibit 99.1).